Department of Neurology, Emory University School of Medicine, and Emory Sleep Center, Emory Healthcare, 12 Executive Park Dr NE, Atlanta, GA, 30329, USA.
Service des Pathologies du Sommeil, Centre National de Reference des Hypersomnies Rares, Hôpitaux Universitaires Pitié-Salpêtrière, Sorbonne Université, Paris, 75013, France.
Neurotherapeutics. 2021 Jan;18(1):20-31. doi: 10.1007/s13311-020-00919-1.
There are numerous disorders of known or presumed neurologic origin that result in excessive daytime sleepiness, collectively known as the central disorders of hypersomnolence. These include narcolepsy types 1 and 2, idiopathic hypersomnia, Kleine-Levin syndrome, and hypersomnia due to or associated with medical disease, neurologic disease, psychiatric disease, medications or substances, and insufficient sleep durations. This chapter focuses on the treatment of nonnarcoleptic hypersomnia syndromes, from those that are commonly encountered in neurologic practice, such as hypersomnia due to Parkinson's disease, to those that are exceedingly rare but present with dramatic manifestations, such as Kleine-Levin syndrome. The level of evidence for the treatment of sleepiness in these disorders is generally lower than in the well-characterized syndrome of narcolepsy, but available clinical and randomized, controlled trial data can provide guidance for the management of each of these disorders. Treatments vary by diagnosis but may include modafinil/armodafinil, traditional psychostimulants, solriamfetol, pitolisant, clarithromycin, flumazenil, sodium oxybate, melatonin, methylprednisolone, and lithium.
有许多已知或推测为神经起源的疾病会导致日间过度嗜睡,统称为中枢性睡眠增多症。这些疾病包括 1 型和 2 型发作性睡病、特发性嗜睡症、周期性嗜睡贪食症以及与医学疾病、神经疾病、精神疾病、药物或物质、睡眠时间不足相关或与之相关的嗜睡症。本章重点介绍非发作性嗜睡症综合征的治疗,包括在神经科实践中常见的如帕金森病相关的嗜睡症,以及极为罕见但表现明显的疾病,如周期性嗜睡贪食症。这些疾病的嗜睡症治疗证据水平通常低于已明确的发作性睡病综合征,但现有的临床和随机对照试验数据可以为每种疾病的治疗提供指导。治疗方法因诊断而异,但可能包括莫达非尼/阿莫达非尼、传统精神兴奋剂、索立德生、吡咯戊酮、克拉霉素、氟马西尼、羟丁酸钠、褪黑素、甲基强的松龙和锂。